tiprankstipranks
Compass Pathways Plc (CMPS)
NASDAQ:CMPS
US Market
Want to see CMPS full AI Analyst Report?

COMPASS Pathways (CMPS) Stock Forecast & Price Target

2,434 Followers
See the Price Targets and Ratings of:

CMPS Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
COMPASS
Pathways
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CMPS Stock 12 Month Forecast

Average Price Target

$23.50
▲(252.85% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for COMPASS Pathways in the last 3 months. The average price target is $23.50 with a high forecast of $70.00 and a low forecast of $14.00. The average price target represents a 252.85% change from the last price of $6.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","71":"$71","19.25":"$19.25","36.5":"$36.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,19.25,36.5,53.75,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.01,13.701538461538462,18.393076923076926,23.084615384615386,27.776153846153846,32.46769230769231,37.159230769230774,41.85076923076923,46.542307692307695,51.23384615384616,55.92538461538462,60.61692307692308,65.30846153846154,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.01,10.124615384615385,11.239230769230769,12.353846153846153,13.468461538461538,14.583076923076923,15.697692307692307,16.81230769230769,17.926923076923075,19.041538461538458,20.156153846153845,21.270769230769233,22.385384615384616,{"y":23.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.01,9.393846153846154,9.777692307692307,10.161538461538461,10.545384615384615,10.929230769230768,11.313076923076924,11.696923076923078,12.080769230769231,12.464615384615385,12.848461538461539,13.232307692307693,13.616153846153846,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.77,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.01,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$23.50Lowest Price Target$14.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CMPS
H.C. Wainwright
H.C. Wainwright
$70
Buy
951.05%
Upside
Reiterated
05/18/26
H.C. Wainwright Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
LifeSci Capital Analyst forecast on CMPS
LifeSci Capital
LifeSci Capital
$23
Buy
245.35%
Upside
Assigned
05/16/26
Compass Pathways: Buy Rating Reiterated on COMP360 Progress and TRD Commercial Potential; $23 Price Target Unchanged
Maxim Group Analyst forecast on CMPS
Maxim Group
Maxim Group
$20
Buy
200.30%
Upside
Assigned
05/15/26
Compass Pathways price target raised to $20 from $12 at MaximCompass Pathways price target raised to $20 from $12 at Maxim
Jefferies Analyst forecast on CMPS
Jefferies
Jefferies
$18
Buy
170.27%
Upside
Reiterated
05/14/26
Jefferies Remains a Buy on COMPASS Pathways (CMPS)
Canaccord Genuity Analyst forecast on CMPS
Canaccord Genuity
Canaccord Genuity
$18
Buy
170.27%
Upside
Reiterated
05/14/26
COMPASS Pathways (CMPS) Gets a Buy from Canaccord Genuity
Morgan Stanley Analyst forecast on CMPS
Morgan Stanley
Morgan Stanley
$16$17
Buy
155.26%
Upside
Assigned
05/14/26
Compass Pathways price target raised to $17 from $16 at Morgan StanleyCompass Pathways price target raised to $17 from $16 at Morgan Stanley
TD Cowen Analyst forecast on CMPS
TD Cowen
TD Cowen
$29
Buy
335.44%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: DarioHealth (NASDAQ: DRIO), NeuroOne Medical Technologies (NASDAQ: NMTC) and COMPASS Pathways (NASDAQ: CMPS)
RBC Capital Analyst forecast on CMPS
RBC Capital
RBC Capital
$21$22
Buy
230.33%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Biogen (NASDAQ: BIIB) and COMPASS Pathways (NASDAQ: CMPS)
BTIG
$14
Buy
110.21%
Upside
Reiterated
05/13/26
Buy Rating Reiterated on COMPASS Pathways as Regulatory Backdrop Improves and COMP360 Outlook Strengthens; $14 Price Target Maintained
Oppenheimer Analyst forecast on CMPS
Oppenheimer
Oppenheimer
$20
Buy
200.30%
Upside
Reiterated
04/24/26
Oppenheimer says CNPV designation strengthens case for Compass Pathways' COMP360Oppenheimer says CNPV designation strengthens case for Compass Pathways' COMP360
B. Riley Securities Analyst forecast on CMPS
B. Riley Securities
B. Riley Securities
$17
Buy
155.26%
Upside
Initiated
04/24/26
Compass Pathways initiated with a Buy at B. RileyCompass Pathways initiated with a Buy at B. Riley
Stifel Nicolaus Analyst forecast on CMPS
Stifel Nicolaus
Stifel Nicolaus
$11$14
Buy
110.21%
Upside
Reiterated
03/25/26
Compass Pathways price target raised to $14 from $11 at StifelCompass Pathways price target raised to $14 from $11 at Stifel
Evercore ISI
$8
Hold
20.12%
Upside
Reiterated
02/06/26
COMPASS Pathways (CMPS) Gets a Hold from Evercore ISI
Cantor Fitzgerald Analyst forecast on CMPS
Cantor Fitzgerald
Cantor Fitzgerald
$20
Buy
200.30%
Upside
Reiterated
01/07/26
Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CMPS
H.C. Wainwright
H.C. Wainwright
$70
Buy
951.05%
Upside
Reiterated
05/18/26
H.C. Wainwright Sticks to Their Buy Rating for COMPASS Pathways (CMPS)
LifeSci Capital Analyst forecast on CMPS
LifeSci Capital
LifeSci Capital
$23
Buy
245.35%
Upside
Assigned
05/16/26
Compass Pathways: Buy Rating Reiterated on COMP360 Progress and TRD Commercial Potential; $23 Price Target Unchanged
Maxim Group Analyst forecast on CMPS
Maxim Group
Maxim Group
$20
Buy
200.30%
Upside
Assigned
05/15/26
Compass Pathways price target raised to $20 from $12 at MaximCompass Pathways price target raised to $20 from $12 at Maxim
Jefferies Analyst forecast on CMPS
Jefferies
Jefferies
$18
Buy
170.27%
Upside
Reiterated
05/14/26
Jefferies Remains a Buy on COMPASS Pathways (CMPS)
Canaccord Genuity Analyst forecast on CMPS
Canaccord Genuity
Canaccord Genuity
$18
Buy
170.27%
Upside
Reiterated
05/14/26
COMPASS Pathways (CMPS) Gets a Buy from Canaccord Genuity
Morgan Stanley Analyst forecast on CMPS
Morgan Stanley
Morgan Stanley
$16$17
Buy
155.26%
Upside
Assigned
05/14/26
Compass Pathways price target raised to $17 from $16 at Morgan StanleyCompass Pathways price target raised to $17 from $16 at Morgan Stanley
TD Cowen Analyst forecast on CMPS
TD Cowen
TD Cowen
$29
Buy
335.44%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: DarioHealth (NASDAQ: DRIO), NeuroOne Medical Technologies (NASDAQ: NMTC) and COMPASS Pathways (NASDAQ: CMPS)
RBC Capital Analyst forecast on CMPS
RBC Capital
RBC Capital
$21$22
Buy
230.33%
Upside
Reiterated
05/13/26
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Biogen (NASDAQ: BIIB) and COMPASS Pathways (NASDAQ: CMPS)
BTIG
$14
Buy
110.21%
Upside
Reiterated
05/13/26
Buy Rating Reiterated on COMPASS Pathways as Regulatory Backdrop Improves and COMP360 Outlook Strengthens; $14 Price Target Maintained
Oppenheimer Analyst forecast on CMPS
Oppenheimer
Oppenheimer
$20
Buy
200.30%
Upside
Reiterated
04/24/26
Oppenheimer says CNPV designation strengthens case for Compass Pathways' COMP360Oppenheimer says CNPV designation strengthens case for Compass Pathways' COMP360
B. Riley Securities Analyst forecast on CMPS
B. Riley Securities
B. Riley Securities
$17
Buy
155.26%
Upside
Initiated
04/24/26
Compass Pathways initiated with a Buy at B. RileyCompass Pathways initiated with a Buy at B. Riley
Stifel Nicolaus Analyst forecast on CMPS
Stifel Nicolaus
Stifel Nicolaus
$11$14
Buy
110.21%
Upside
Reiterated
03/25/26
Compass Pathways price target raised to $14 from $11 at StifelCompass Pathways price target raised to $14 from $11 at Stifel
Evercore ISI
$8
Hold
20.12%
Upside
Reiterated
02/06/26
COMPASS Pathways (CMPS) Gets a Hold from Evercore ISI
Cantor Fitzgerald Analyst forecast on CMPS
Cantor Fitzgerald
Cantor Fitzgerald
$20
Buy
200.30%
Upside
Reiterated
01/07/26
Cantor Fitzgerald Sticks to Its Buy Rating for COMPASS Pathways (CMPS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering COMPASS Pathways

3 Months
Success Rate
8/14 ratings generated profit
57%
Average Return
+18.26%
Copying Thomas Shrader's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +18.26% per trade.
1 Year
Leonid TimashevRBC Capital
Success Rate
9/13 ratings generated profit
69%
Average Return
+49.02%
Copying Leonid Timashev's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +49.02% per trade.
2 Years
Leonid TimashevRBC Capital
Success Rate
12/13 ratings generated profit
92%
Average Return
+89.03%
Copying Leonid Timashev's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +89.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMPS Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
15
19
29
28
29
Buy
1
1
1
1
2
Hold
1
2
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
22
31
30
31
In the current month, CMPS has received 31 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CMPS average Analyst price target in the past 3 months is 23.50.
Each month's total comprises the sum of three months' worth of ratings.

CMPS Financial Forecast

CMPS Earnings Forecast

Next quarter’s earnings estimate for CMPS is -$0.40 with a range of -$0.70 to -$0.27. The previous quarter’s EPS was $0.71. CMPS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CMPS has Performed in-line its overall industry.
Next quarter’s earnings estimate for CMPS is -$0.40 with a range of -$0.70 to -$0.27. The previous quarter’s EPS was $0.71. CMPS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year CMPS has Performed in-line its overall industry.
No data currently available

CMPS Sales Forecast

Next quarter’s sales forecast for CMPS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CMPS has Performed in-line its overall industry.
Next quarter’s sales forecast for CMPS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year CMPS has Performed in-line its overall industry.

CMPS Stock Forecast FAQ

What is CMPS’s average 12-month price target, according to analysts?
Based on analyst ratings, Compass Pathways Plc’s 12-month average price target is 23.50.
    What is CMPS’s upside potential, based on the analysts’ average price target?
    Compass Pathways Plc has 252.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CMPS a Buy, Sell or Hold?
          Compass Pathways Plc has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Compass Pathways Plc’s price target?
            The average price target for Compass Pathways Plc is 23.50. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $70.00 ,the lowest forecast is $14.00. The average price target represents 252.85% Increase from the current price of $6.66.
              What do analysts say about Compass Pathways Plc?
              Compass Pathways Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of CMPS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.